TreVita, a U.S.-based medical travel company, announced on September 23, 2026, the expansion of its regenerative medicine program in Zona Río, Baja California, Mexico, broadening its stem cell services across additional therapeutic areas, including healthy aging and rejuvenation, sports and orthopedic injuries, among others. The expansion reflects TreVita’s growing focus on regenerative medicine as a core part of its medical travel platform, according to a press release issued via NEWMEDIAWIRE.
The company is emphasizing individualized physician evaluation rather than predetermined treatment packages, along with greater transparency around cell source, count, viability, testing, and documentation. TreVita provides end-to-end support, from medical review and treatment planning through travel coordination, treatment, and post-care follow-up. “Regenerative medicine is an increasingly important part of the healthcare conversation, but it is also a category where clients need clarity, transparency and strong medical oversight,” said Blake Schroeder, CEO of TreVita. “Our goal is to help clients understand their options, remove barriers, connect them with experienced physicians and create a care experience built around safety, care, integrity and support – and most importantly, increased healthspan.”
The program begins with an individualized medical review where physicians evaluate a client’s medical history, current condition, diagnostic information, and treatment goals before determining candidacy and the appropriate approach. A central focus is transparency around the cellular products clients receive, including explaining cell type and source, cell count, cell viability, delivery method, and providing testing and documentation to each client, along with the physician’s rationale for the treatment plan. This approach aligns with TreVita’s core values of prioritizing safety, providing clear information, and operating with integrity while developing individualized plans that may include multiple sessions when medically appropriate.
The expansion comes as interest in regenerative medicine grows among Americans seeking new approaches to health, recovery, and longevity. Grand View Research estimates that the U.S. regenerative medicine market generated approximately $19.5 billion in 2024 and projects it will reach $49.3 billion by 2030, growing at a compound annual rate of approximately 16.8% from 2025 through 2030. For TreVita, this growth supports a broader long-term investment in regenerative medicine. The company is developing additional clinical and laboratory capabilities in Zona Rio to give it greater involvement across the client journey, from medical evaluation and treatment coordination to cellular quality oversight and follow-up care.
“Our vision is to increase healthspan for our clients. That is far broader than a company that simply helps someone travel for a procedure,” Schroeder added. “We are building a regenerative medicine platform where the physicians, the science, the cellular product and the client experience are connected. As we expand, that level of transparency and accountability will continue to guide what we build.” TreVita, headquartered in San Diego, partners with a network of vetted physicians in Mexico and worldwide, offering support across bariatric surgery, plastic surgery, hair transplant, and regenerative medicine. The company’s regenerative services are available to qualifying clients through its U.S.-based care team, and it does not represent stem cell therapies as cures or guarantee outcomes.
For more information, visit TreVita.
